Home » OSI’s Tarceva Turned Down for First-Line Indication
OSI’s Tarceva Turned Down for First-Line Indication
December 18, 2009
An FDA advisory panel has recommended the agency reject expanded use of OSI Pharmaceuticals’ Tarceva as first-line maintenance treatment for patients
with stable nonsmall cell lung cancer (NSCLC) after agency staff raised concerns about the drug’s benefit.